Genentech is a biotechnology company that discovers and develops medicines for serious and life-threatening diseases, working across research, personalized medicine, and biopharmaceutical manufacturing as part of the Roche Group.
Genentech is a biotechnology company that discovers and develops medicines for people with serious and life-threatening diseases. Founded in 1976 and operating as a member of the Roche Group, the company works across drug discovery and development, clinical research, personalized medicine, and biopharmaceutical manufacturing, with operations in the United States and a global footprint through Roche. Areas of technical focus include biomedical research, AI for molecule discovery, and manufacturing at scale.
On the applied side, the company reports using state-of-the-art manufacturing facilities and integrating AI into molecule discovery - the environments where automation, instrumentation, and control work intersect with lab and production workflows. Its stated technical commitments include a $50 billion investment in U.S. manufacturing and R&D, alongside nearly 50 years of continuous operation. Research priorities span oncology, neurology and multiple sclerosis, and personalized medicine, with efforts to lower barriers to clinical trial participation and broaden who is represented in research.
Among its development milestones, Genentech cites the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. The organization describes a science-driven culture that draws on expertise across the Roche Group, with engineering work grounded in regulated biopharmaceutical production, clinical research operations, and discovery tooling.
